Our results are consistent with a study showing that a single oral dose of simvastatin prior to the induction of renal ischemia reduces tubulointerstitial KIM-1 immunoreactivity along with reducing impairments in peritubular microvascular permeability and perfusion, glomerular barrier disruption, tubular dysfunction, and acute kidney injury [58]. The gene discussed is HAVCR1; the disease is acute kidney injury.